Investment in blood cancer research has saved nearly 26 million years of life, but disparities remain
Over the past 75 years, advances in the treatment of major blood cancers have saved more than 25 million years of life in the United States, according to results of an analysis led by researchers at Blood Cancer United and published in Blood Advances. But the gains have not reached everyone equally: survival progress remains limited for people diagnosed with acute myeloid leukemia (AML) and for…
Investment in blood cancer research has led to the saving of nearly 26 million years of life in the United States over the past 75 years, according to a study led by Blood Cancer United and published in Blood Advances. However, the benefits of these advancements have not been equally distributed, with survival progress remaining limited for patients diagnosed with acute myeloid leukemia (AML) and for Black individuals across most major blood cancer types.
The study, which analyzed data from 1949 to 2024, found that advances in treatment have saved 25.8 million life-years, with the greatest gains seen in Hodgkin lymphoma, acute lymphoblastic leukemia, and non-Hodgkin lymphoma. Despite these successes, the analysis highlights the need for continued investment in research to address disparities and improve outcomes for all patients.
Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
